Tenax Therapeutics (TENX) Reaches New 52-Week Low at $2.51

Tenax Therapeutics Inc (NASDAQ:TENX) hit a new 52-week low on Monday . The stock traded as low as $2.51 and last traded at $2.57, with a volume of 2197 shares trading hands. The stock had previously closed at $3.25.

Separately, ValuEngine raised Tenax Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, November 7th.

A hedge fund recently raised its stake in Tenax Therapeutics stock. Renaissance Technologies LLC grew its stake in Tenax Therapeutics Inc (NASDAQ:TENX) by 45.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,400 shares of the specialty pharmaceutical company’s stock after buying an additional 26,200 shares during the period. Renaissance Technologies LLC owned 5.75% of Tenax Therapeutics worth $526,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.18% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2018/11/27/tenax-therapeutics-tenx-reaches-new-52-week-low-at-2-51.html.

About Tenax Therapeutics (NASDAQ:TENX)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.

Featured Story: What is a stock split?

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply